Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 2,673 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control II Clear all

Conditions: Low Back Pain
Interventions: lumbar transforaminal epidural injections; Procedure
Lead sponsor: Pain Management Center of Paducah; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Cutaneous Melanoma, Stage II
Interventions: Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin; Procedure
Lead sponsor: Melanoma and Skin Cancer Trials Limited; Other
Eligibility: 18 Years and older
Enrollment: 2,998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2034
U.S. locations: 128
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more

Conditions: Alzheimer's Disease or Vascular Dementia
Interventions: BAC treatment, Matched vehicle; Drug
Lead sponsor: Charsire Biotechnology Corp.; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more

Conditions: Neoplasm Metastasis, Palliative Care
Interventions: Tanezumab 10 mg IV, IV Placebo for tanezumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 12
States / cities: La Jolla, California • South Bend, Indiana • Shreveport, Louisiana + 2 more

Conditions: COVID
Interventions: Estradiol patch; Drug
Lead sponsor: Sharon Nachman; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Multiple Sclerosis
Interventions: rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Phoenix, Arizona • Loma Linda, California • Modesto, California + 28 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort); Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 80
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Prostate Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement; Procedure · Drug · Dietary Supplement
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 798
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more

Conditions: Post Traumatic Stress Disorder
Interventions: 16-Week Group Treatment; Behavioral
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 19 Years to 75 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Retinitis Pigmentosa
Interventions: SPVN06; Drug
Lead sponsor: SparingVision; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • Portland, Oregon + 2 more

Conditions: Schizophrenia
Interventions: BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 21
States / cities: Garden Grove, California • Lemon Grove, California • Orange, California + 17 more

Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more

Conditions: Cancer
Interventions: mycophenolate mofetil, placebo; Drug
Lead sponsor: Martin, Paul; Other
Eligibility: 4 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 15
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 11 more

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more

Conditions: Clonal Cytopenia of Undetermined Significance
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, Chest Radiography, Echocardiography, Placebo Administration, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: Uma Borate; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Miami, Florida • New York, New York • Columbus, Ohio + 2 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Ifetroban Sodium, Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: La Mesa, California • San Francisco, California • Farmington, Connecticut + 17 more

Conditions: Obesity
Interventions: Escalating Lottery; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 80 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Neoplasms, Early Detection of Cancer
Interventions: Patient activation, Primary care physician activation, Control; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 25 Years and older · Female only
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: New York, New York • Durham, North Carolina • Memphis, Tennessee

Conditions: Obstructed Defecation Syndrome (ODS)
Interventions: Botulinum Toxin-A, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer Survivor, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions: Behavioral Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Los Angeles, California • Riverside, California

Conditions: Muscle Tear
Interventions: ADRCs prepared by investigational Celution Device, Placebo; Device · Biological
Lead sponsor: Cytori Therapeutics; Industry
Eligibility: 20 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Gingivitis, Investigation of Biological Markers of Inflammation
Interventions: Iocide Oral Rinse, Placebo; Drug
Lead sponsor: Biomedical Development Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Inguinal Hernia
Interventions: TLC590, Naropin; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Draper, Utah

Search by objective public record fields.

Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

Estrogen Patch for COVID-19 Symptoms

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Effectiveness of Cognitive, Exposure, and Skills Group Manualized Treatments in Operations Iraqi (OIF)/Operation Enduring Freedom (OEF) Female Veterans

Promising ROd-cone DYstrophy Gene therapY

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

The Weigh Forward, Financial Incentives for Maintenance of Weight Loss

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Effects of Botox in Obstructed Defecation Syndrome

Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors

Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

Efficacy of Iocide Oral Rinse Against Gingival Inflammation

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management